3901 - 3910 of 9148 Results
Title
Year
- Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial2022RESTRICTEDTitle: Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trialJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 12Start Page: 1099End Page: 1109Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00400-8Citation Count: 204
- Major advances in Parkinson's disease over the past two decades and future research directions2022RESTRICTEDTitle: Major advances in Parkinson's disease over the past two decades and future research directionsJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 12Start Page: 1076End Page: 1079Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00448-3Citation Count: 18
- Inconsistency and incongruence: the two diagnostic pillars of functional movement disorder2022RESTRICTEDTitle: Inconsistency and incongruence: the two diagnostic pillars of functional movement disorderJournal Name: The LancetPublisher: Elsevier BVVol: 400Issue #: 10348Start Page: 328End Page: 328Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s0140-6736(22)01184-9Citation Count: 12
- Optimizing the reaction conditions for the GMP production of [18F]ACI-12589, a promising candidate in the development as a PET tracer targeting α-synuclein2022RESTRICTEDTitle: Optimizing the reaction conditions for the GMP production of [18F]ACI-12589, a promising candidate in the development as a PET tracer targeting α-synucleinJournal Name: Nuclear Medicine and BiologyPublisher: Elsevier BVVol: 108-109Issue #:Start Page: S87End Page: S88Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s0969-8051(22)00207-4Citation Count: 0
- Mild and direct 18F radiofluorination of tetrazines through sulfonium salt precursors2022RESTRICTEDTitle: Mild and direct 18F radiofluorination of tetrazines through sulfonium salt precursorsJournal Name: Nuclear Medicine and BiologyPublisher: Elsevier BVVol: 108-109Issue #:Start Page: S88End Page: S89Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s0969-8051(22)00209-8Citation Count: 0
-
OPENTitle: Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational studyJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 20Issue #: 3Start Page: 203End Page: 212Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(20)30449-xBest OA location URL: http://hdl.handle.net/2445/214932Citation Count: 331
- The GBA-370Rec Parkinson's disease risk haplotype harbors a potentially pathogenic variant in the mitochondrial gene SLC25A442021RESTRICTEDTitle: The GBA-370Rec Parkinson's disease risk haplotype harbors a potentially pathogenic variant in the mitochondrial gene SLC25A44Journal Name: Molecular Genetics and MetabolismPublisher: Elsevier BVVol: 133Issue #: 1Start Page: 109End Page: 112Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.ymgme.2021.03.012Citation Count: 4
-
OPENTitle: Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned ratJournal Name: European Journal of PharmacologyPublisher: Elsevier BVVol: 929Issue #:Start Page: 175090End Page: 175090Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.ejphar.2022.175090Best OA location URL: https://doi.org/10.1016/j.ejphar.2022.175090Citation Count: 19
-
OPENTitle: Movement Disorders and SARS‐CoV‐2Journal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 10Issue #: S2Start Page: S9End Page: S17Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mdc3.13615Best OA location URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10448146/pdf/MDC3-10-S9.pdfCitation Count: 4
-
OPENTitle: Compensation Strategies for Gait Impairments in Parkinson's Disease: From Underlying Mechanisms to Daily Clinical PracticeJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 10Issue #: S2Start Page: S56End Page: S62Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/mdc3.13616Best OA location URL: https://doi.org/10.1002/mdc3.13616Citation Count: 12